Form 4: Xilio Therapeutics Director Sara Bonstein Granted Stock Options

Director Sara Bonstein of Xilio Therapeutics, Inc. was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.02 on June 14, 2024.

Summary

• Sara Bonstein, a director of Xilio Therapeutics, Inc., filed a Form 4 on June 17, 2024, reporting a transaction.
• On June 14, 2024, Bonstein was granted stock options for 25,000 shares of Xilio Therapeutics common stock.
• The exercise price of the options is $1.02 per share.
• The options vest on the earlier of June 14, 2025, or the date of the Issuer's next annual meeting of stockholders following the grant date, contingent upon continued service to the Issuer.
• Bonstein also signed a Limited Power of Attorney, effective June 12, 2024, authorizing Ren Russo, Christopher Frankenfield, Kevin Brennan, and Julia Walcott to act on her behalf for Section 16 reporting obligations.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no indications of negative news or concerns.

Positives

• The grant of stock options to a director aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is tied to continued service, suggesting an expectation of ongoing contributions from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and officers in publicly traded companies, particularly in the biotech sector.
• Vesting schedules tied to continued service and/or performance milestones are also common practice.
• Comparing the size of the grant (25,000 shares) and the exercise price ($1.02) to similar grants at comparable biotech companies would require further research into industry benchmarks and company-specific factors.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• The director benefits from the potential to profit from an increase in the company's stock price.

Key Dates